ArticleGastroenterology clinics of North America2014
Steroids in pediatric eosinophilic esophagitis.
Article in Gastroenterology clinics of North America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 15 citations in OpenAlex.
- Dupilumab as an effective therapy for eosinophilic esophagitis in pediatric patients weighing less than 15 kilograms.JPGN reports · 2026Article
- Systematic review of histological remission criteria in eosinophilic esophagitis.JGH open : an open access journal of gastroenterology and hepatology · 2018Review
- Recent discoveries and emerging therapeutics in eosinophilic esophagitis.World journal of gastrointestinal pharmacology and therapeutics · 2016Review
- Eosinophilic esophagitis: From pathophysiology to treatment.World journal of gastrointestinal pathophysiology · 2015Review
- Translating new developments in eosinophilic esophagitis pathogenesis into clinical practice.Current treatment options in gastroenterology · 2015Article
- Topical steroid therapy for eosinophilic esophagitis.Gastroenterology & hepatology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Swallowed fluticasone and oral viscous budesonide are effective first-line therapies for eosinophilic esophagitis in children. Side effects are minimal without evidence of Cushing syndrome, as seen in treatment with systemic corticosteroids. New studies on alternative delivery systems and different corticosteroids (eg, ciclesonide) are encouraging. As knowledge of corticosteroids in eosinophilic esophagitis expands, newer questions continue to arise concerning dose, delivery, and choice of corticosteroids; long-term adverse effects; and maintenance therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.